Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02247726 · ClinicalTrials.gov registry record · Phase 2
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
A Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT02247726 is a Phase 2 study of Respiratory Syncytial Virus Infections that has completed, run by Novavax. The registered enrollment target is 50 participants, below the 1,089-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT02247726, a Phase 2 study of Respiratory Syncytial Virus Infections, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy third-trimester pregnant women and to assess the impact of maternal immunization on infant safety through one year of life.
Conditions Studied
Interventions
- DRUG Saline Placebo (0.5mL injection)
- DRUG RSV F vaccine (0.5mL injection)
Study Locations (7)
Kansas
- Hutchinson Clinic, P.A. - Hutchinson
- University of Kansas Medical Center Research Institute - Kansas City
Idaho
- Advanced Specialty Research - Nampa
Nebraska
- Meridian Clinical Research - Norfolk
North Carolina
- Duke University - Durham
Pennsylvania
- Magee- Womens Hospital of UPMC - Pittsburgh
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02247726
The ClinicalTrials.gov registry entry for NCT02247726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,089-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (95% lower). The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which Saline Placebo (0.5mL injection) is the first listed.
NCT02247726 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Kansas, Idaho, Nebraska.
Frequently Asked Questions
What is clinical trial NCT02247726 about?
NCT02247726 is a clinical study titled "RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.". The purpose of this study is to evaluate the safety and immunogenicity of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy third-trimester pregnant women and to assess the impact of maternal immunization on infant safety through one year of life.
What is the current status of trial NCT02247726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2014-09. Estimated completion is 2016-07.
What conditions does trial NCT02247726 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT02247726?
The interventions under investigation include: Saline Placebo (0.5mL injection) (DRUG), RSV F vaccine (0.5mL injection) (DRUG).
Who is sponsoring clinical trial NCT02247726?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02247726 being conducted?
This trial has 7 study locations across Idaho, Kansas, Nebraska, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
RECRUITING · Phase 2
-
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
RECRUITING · Phase 2
-
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
COMPLETED · Phase 2
-
A Study of BLB-201 RSV Vaccine in Infants and Children
RECRUITING · Phase 1
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.